A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.
暂无分享,去创建一个
Ralph Buchert | Rainer Thomasius | Oliver Schulze | Malte Clausen | Florian Wilke | Kay Petersen | R. Buchert | F. Wilke | R. Thomasius | M. Clausen | K. Petersen | Bruno Nebeling | Jost Obrocki | Ulrich Schmidt | B. Nebeling | O. Schulze | J. Obrocki | Ulrich Schmidt
[1] W. van den Brink,et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. , 2001, Archives of general psychiatry.
[2] J. Langston,et al. Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations a , 1990, Annals of the New York Academy of Sciences.
[3] R. Shank,et al. McN-5652: a highly potent inhibitor of serotonin uptake. , 1988, The Journal of pharmacology and experimental therapeutics.
[4] Jason Ditton,et al. Hair testing: just how accurate is it? , 2002 .
[5] Liesbeth Reneman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[6] K. Petersen,et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users , 2003, Psychopharmacology.
[7] L. Itti,et al. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study , 2000, Psychiatry Research: Neuroimaging.
[8] F. Vollenweider,et al. Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram , 1999, Neuropsychopharmacology.
[9] Ralph Buchert,et al. Improved Statistical Power of the Multilinear Reference Tissue Approach to the Quantification of Neuroreceptor Ligand Binding by Regularization* , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] Robert B. Innis,et al. Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] R. de la Torre,et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. , 1999, The Journal of pharmacology and experimental therapeutics.
[12] Simon M. Ametamey,et al. Evaluation of Serotonergic Transporters using PET and [11C](+)McN-5652: Assessment of Methods , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[13] John Hilton,et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] M Fujita,et al. Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers , 2001, Synapse.
[15] Klaus P. Ebmeier,et al. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.
[16] E. D. De Souza,et al. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. , 1988, European journal of pharmacology.
[17] H. Kung,et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] S. Kish. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.
[19] John Hilton,et al. Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .
[20] Ulrich Müller,et al. Is correction for age necessary in neuroimaging studies of the central serotonin transporter? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[21] A. R. Green,et al. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.
[22] Marc Laruelle,et al. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.
[23] M Slifstein,et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] J. Seibyl,et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. , 2000, The American journal of psychiatry.
[25] W. van den Brink,et al. Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission , 2000, Psychopharmacology.
[26] D. J. Wyper,et al. Validation of Statistical Parametric Mapping (SPM) in Assessing Cerebral Lesions: A Simulation Study , 1999, NeuroImage.
[27] Z. Szabo,et al. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.
[28] R. Buchert,et al. Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET , 2001, Nuclear medicine communications.
[29] S. Kish,et al. Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .
[30] R Coppola,et al. Reduced central serotonin transporters in alcoholism. , 1998, The American journal of psychiatry.
[31] Ralph Buchert,et al. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.